A cancer vaccine developed in Russia could radically change the global cancer treatment industry and pave the way for a new medical paradigm in the treatment of malignant tumors.
Professor Ulvi Saran, president of the Turkish Social Research Fund (KAV), stated this on the social media platform X, writing: "This vaccine has the potential to fundamentally change the global cancer treatment industry and open the door to a new era."
According to the expert, the new vaccine developed in Russia differs fundamentally from traditional treatments such as chemotherapy and radiation. Instead of directly targeting the tumor, this vaccine trains the immune system to recognize and destroy cancer cells.
Saran noted that preliminary study results show the potential to slow tumor growth, reduce the risk of recurrence, and extend patient life. He believes this approach may be safer and more selective than traditional treatments, which are often associated with serious side effects.
The expert emphasized that if the vaccine is widely implemented, it will fundamentally shift the balance of power in the global cancer treatment market, valued at approximately $2.6 trillion. He believes this will accelerate the transition from a model reliant on expensive treatments to a strategy of prevention and immune protection.
Earlier, Russian Health Minister Mikhail Murashko said that the development of the cancer vaccine was proceeding according to plan, and that the first experimental batches of the vaccine had been produced at the factory that was built to produce it.
Prior to that, Murashko announced that the Russian Ministry of Health had approved the clinical use of the mRNA skin cancer vaccine "NEOONCOVAC".
Messenger RNA (mRNA) vaccines are an innovative type of vaccine that uses messenger RNA (mRNA) to code for a disease-causing protein. These vaccines stimulate the body's cells to produce an antigen, triggering an immune response without the use of live viruses. The main types include non-replicating, self-replicating, and dendritic cell-derived mRNA vaccines. These vaccines show promise in infection prevention and cancer treatment.
